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Available online 8 April 2016Guillain–Barre' syndrome (GBS) is an acute, postinfectious, immune-mediated, demyelinating disease of periph-
eral nerves and nerve roots. As a classical animalmodel of GBS, experimental autoimmune neuritis (EAN) has be-
come well-accepted. Additionally, the potent immune modulation exerted by mammalian target of rapamycin
(mTOR) inhibitors has been used to treat cancers and showed beneﬁcial effects. Here we demonstrate that the
mTOR inhibitor RAD001 (everolimus) protected rats from the symptoms of EAN, as shown by decreased paraly-
sis, diminished inﬂammatory cell inﬁltration, reductions in demyelination of peripheral nerves and improved
nerve conduction. Furthermore, RAD001 shifted macrophage polarization toward the protective M2 phenotype
andmodiﬁed the inﬂammatorymilieu by downregulating the production of pro-inﬂammatory cytokines includ-
ing IFN-γ and IL-17as well as upregulating the release of anti-inﬂammatory cytokines such as IL-4 and TGF-β.
Amounts of the mTOR downstream targets p-P70S6K and p-4E-BP1 in sciatic nerves decreased, whereas the
level of its upstream protein p-Akt was elevated. This demonstrated that RAD001 inhibited the mTOR pathway
and encouraged the expression of p-Akt, which led to M2macrophage polarization, thus improved the outcome
of EAN in rats. Consequently, RAD001 exhibits strong potential as a therapeutic strategy for ameliorating periph-
eral poly-neuropathy.







Guillain–Barre' syndrome (GBS) is an autoimmune disease and an
acute inﬂammatory disorder that afﬂicts the peripheral nervous system
(PNS). GBS is presently the most frequent cause of acute ﬂaccid paraly-
sis worldwide, thereby becoming a leading source of serious neurologic
emergencies (Yuki and Hartung, 2012). Proven effective immunother-
apies for GBS are plasma exchange and intravenous immunoglobulin
G. Nevertheless, despite receiving immunotherapy, approximately 5%
of these patients die, and up to 20% suffer from severe disabilities
(Hughes et al., 2007). Clearly this afﬂiction is in urgent need of
resolution.
Experimental autoimmune neuritis (EAN) has been developed as an
animal model of GBS, because it mimics its clinical, histopathologicalperimental autoimmune neuri-
ipheral nervous system; PBS,
ion; EMG, electromyography;
or nerve conduction velocity;
,5-dimethylthiazol-2-yl)-5-(3-
m.
. This is an open access article underand electrophysiological features. EAN is pathologically characterized
by breakdown of the blood-nerve barrier, robust accumulation of reac-
tive T cells andmacrophages into the PNS and demyelination of periph-
eral nerves (Hughes and Cornblath, 2005). During the acute phase, pro-
inﬂammatory cytokines including IL-6, IFN-γ, IL-17 and TNF-α predom-
inate in sciatic nerves and lymphoid organs and mediate inﬂammatory
damage to the peripheral nerves, whereas during the recovery period,
anti-inﬂammatory cytokines such as IL-4 and IL-10 play an essential
role in ending the disease course (Zhang et al., 2013; Zhu et al., 1998).
In addition, phenotypically polarized macrophages generally appear
either in a pro-inﬂammatoryM1mode, i.e., classically activated, or in an
anti-inﬂammatory M2, alternatively activated form (Biswas and
Mantovani, 2010; Sica and Mantovani, 2012). Such changes of macro-
phage polarization in the local environment can have a decisive role in
the pathogenesis of autoimmune and inﬂammatory diseases (Jiang
et al., 2016;Wynnet al., 2013). IFN-γ has given rise to classically activat-
ed macrophages, which secrete IL-1, IL-6 and IL-23. These M1 pheno-
type macrophages are involved in the induction stage of EAN and are
the main contributors to its pathogenic effects and destructive course.
As antibody-dependent cellular cytotoxicity and phagocytosis evolve,
damage to the myelin sheath may ensue due to the production of reac-
tive oxygen intermediates (Hartung et al., 1988). Meanwhile, alterna-
tively activated M2 macrophages arise mainly in response to IL-4the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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covery by promoting T-cell apoptosis, secreting anti-inﬂammatory cyto-
kines like IL-10 and TGF-β (Mantovani et al., 2013) and generating
myelin repair and axonal regeneration (Kiefer et al., 2001). A switch of
macrophage phenotype from classical activation (M1) to alternative ac-
tivation (M2) could change the functions of macrophages from inﬂam-
matory to anti-inﬂammatory accompanied by tissue repair (Mosser and
Edwards, 2008). Therefore, therapies that facilitate the polarization of
macrophages toward the beneﬁcial M2 phenotype may offer protective
effects against EAN.
RAD001 (everolimus), an analog of rapamycin, belongs to a group of
inhibitors for mammalian target of rapamycin (mTOR), which plays a
crucial role in cell proliferation, growth and survival, and mediates its
effects mainly by inhibiting mTORC (mTOR complex) 1, with limited
or no effect on mTORC2 activity (Saran et al., 2015). Currently,
RAD001 is the only mTOR inhibitor approved by the U.S. FDA (Food
and Drug Administration) for the treatment of papillary renal carcino-
ma, pancreatic neuroendocrine tumor, some types of breast cancer
and subependymal giant-cell astrocytoma associated with tuberous
sclerosis (Agarwala and Case, 2010; Baselga et al., 2012; Curran, 2012;
Dorris and Jones, 2014; Yim, 2012). RAD001 has proven effective in re-
ducing those tumors mainly by attenuating the growth of cancer cells
under in vitro and in vivo conditions (Saran et al., 2015). To date,
RAD001 has also exerted a protective effect via the beneﬁcial regulation
of such autoimmune diseases as experimental autoimmune
uveoretinitis (Hennig et al., 2012) and autoimmune hepatitis (Ytting
and Larsen, 2015). Furthermore, as recently shown, activating the
mTOR pathway can downregulate the level of p-Akt, and thus reduce
M2 macrophage polarization (Byles et al., 2013). These results
prompted our detailed examination of the mTOR pathway and macro-
phages polarization in treating EAN.
In this study of EAN, we applied RAD001 in preventative and thera-
peutic patterns and evaluated clinical scores, pathological changes, the
distribution of M1/M2 macrophages and inﬂammatory milieu. As a re-
sult, we found that inhibition of the mTOR pathway and activation of
Akt attenuated the destructive symptoms of EAN.
2. Materials and methods
2.1. Experimental animals and group assignments
Conditions used here for experiments with rats were approved by
the Animal Ethics Committee of the Tianjin Medical University. Lewis
rats (male, 160–190 g, 6–8 weeks old) were purchased from the Vital
River Corporation (Beijing, China). All rats had access to food and
water ad libitum and were acclimated to the vivarium environment,
which was maintained under temperature-control (23 °C ± 2 °C, 12-h
light/dark periods) for oneweek. Animalswere then randomly assigned
to one of three groups (preventative, therapeutic or control, n= 5 per
group). Animal suffering and numbers killed were minimized to the
greatest extent possible.
2.2. Induction of EAN and evaluation of clinical signs
To induce EAN, 300 μl of an inoculant containing 300 μg of dissolved
P0 peptide 180–199 (10 mg/ml; Bio-Synthesis Corporation) was
injected into both hind footpads of each rat. The peptide was dissolved
in phosphate-buffered saline (PBS) (2mg/ml) and then emulsiﬁedwith
an equal volume of complete Freund's adjuvant (CFA; Difco) containing
Mycobacterium tuberculosis (strain H37RA) to a ﬁnal concentration of
1 mg/ml. Following immunization, clinical signs of EAN were scored
daily in a blinded protocol by two different examiners as follows: 0 =
normal; 1= reduced tonus of the tail; 2= limp tail; 3=absent righting
reﬂex; 4 = gait ataxia; 5 =mild paresis of the hind limbs; 6 =moder-
ate paraparesis; 7= severe paraparesis or paraplegia of the hind limbs;
8 = tetraparesis; 9 = moribund; and 10 = death.2.3. RAD001 treatment
RAD001 (everolimus) (5 mg/tablet, Novartis) was dissolved in 2 ml
ethanol and further diluted in ddWater (endotoxin-free) to a ﬁnal con-
centration of 0.2 mg/ml. For preventative treatment, RAD001 solution
was administered by oral gavage (1 mg/kg body weight/day) for 16
consecutive days post-immunization (dpi). For therapeutic treatment,
the same dose of RAD001 solution was administered by oral gavage
daily from the day when the ﬁrst clinical signs were observed, namely
from dpi 7 to 16. Control animals received the same volume of the vehi-
cle solution (i.e., 0.08% ethanol/ddWater). The dosage of RAD001 was
based on our previous investigation using different doses (3, 1 and
0.3mg/kg, daily). The animals treatedwith 3mg/kgdose showed higher
mortality rate and severe adverse effects: diarrhea, weight loss those
were not observed with 1 mg/kg and 0.3 mg/kg daily. And it seemed
that 1 mg/kg can exert more signiﬁcant effect on ameliorating EAN
symptoms.
2.4. Electrophysiological studies
Electromyographic (EMG) recordings of the left sciatic nerve in EAN
rats were executed on dpi 16 with a fully digital Keypoint Compact
EMG/NCS/EP recording system (Dantec Co.). A single blind trial method
was applied to record evoked compound muscle action potential
(CMAP) amplitudes and latencies of sciatic nerves, as previously de-
scribed (Sarkey et al., 2007). Rats were anesthetized ﬁrst with chloral
hydrate (intraperitoneally, 3 mg/kg). Two pairs of monopolar needle
electrodes were used to stimulate the sciatic nerve and record the sig-
nals, respectively. After exposing the left sciatic nerve from the hip
(proximal) to the ankle (distal), one pair of needle electrodes was
inserted at the sciatic notch (hip/proximal) or the ankle (ankle/distal).
The nerve stimulation parameters used to elicit CMAPs were: 1 Hz
pulses, with each pulse being 5mA in amplitude and 0.3ms in duration.
The recording electrodes were positioned in the “belly” part of the gas-
trocnemiusmuscle to record evoked potentials from stimulating the sci-
atic nerve. Themotor nerve conduction velocity (MNCV)was calculated
by measuring the distance between stimulating cathode electrodes and
then measuring the latency difference. The amplitude was calculated
from the baseline to the maximal peak under the resulting CMAP
curves. After electrophysiologic measurements were completed, the in-
cisionwas sutured under an aseptic environment. Body temperatures of
rats during electrophysiologic measurements were maintained above
34 °C by positioning a heating pad under the rat. For each animal, trip-
licate measurements were made.
2.5. Histopathological assessment
Followingnerve conduction studies, ratswere perfused pericardially
with cold PBS followed by 4% paraformaldehyde (Solarbio). Then the
sciatic nerveswere rapidly removed and post-ﬁxed in 4% paraformalde-
hyde overnight at 4 °C. After dehydration using graded ethanol and vit-
riﬁcation by dimethylbenzene, the nerves were embedded in parafﬁn
(Aladdin). Cross sections 6 μm thick were cut with a microtome (Leica
RM2255), mounted on poly-L-lysine-coated slides and stored at room
temperature until stained. Hematoxylin-eosin (H&E) (Solarbio) and
luxol fast blue (LFB) stains were applied separately to evaluate the ex-
tent of inﬂammatory cell inﬁltration and demyelination. Results were
visualized with a Nikon Coolscope digital microscope. To quantify the
inﬂammatory cell inﬁltration, 5 ﬁelds of each slide were acquired; pic-
tures of each group were collected from 4 different rats. To evaluate
the severity of demyelination, histological scores were calculated from
ﬁelds acquired as described above according to the following semi-
quantitative pathological/histological scale: 0, normal perivascular
area; 1, mild cellular inﬁltrate adjacent to the vessel; 2, cellular inﬁltra-
tion plus demyelination in immediate proximity to the vessel; 3, cellular
inﬁltration and demyelination throughout the section. Cell numbers
Table 1
Primers sequences for real-time quantitative RT-PCR.











108 R. Han et al. / Experimental Neurology 280 (2016) 106–114and histological scores were calculated per squaremillimeter from each
ﬁeld (200× magniﬁcation). All counts were performed in a blinded
fashion.
2.6. Lymphocyte proliferation assay
Antigen-speciﬁc lymphocyte proliferationwasmeasured byMTS (3-
(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium) assays as described previously (Xiao et al.,
2014). Brieﬂy, spleens were removed under aseptic conditions and
splenocyteswere harvested. Single-cell suspensions of splenicmononu-
clear cells (MNCs) at a density of 2 × 106 cells/ml were allocated with
100 μl culture medium into 96-well microtiter plates. The culture medi-
um was RPMI1640 (containing 2.05 mM glutamine; HyClone) supple-
mented with 1% (v/v) HEPES buffer solution (Gibco), 0.1% (v/v) 2-
mercaptoethanol (Gibco), 1% (v/v) sodium pyruvate (Gibco), 1% (v/v)
Pen Strep (Gibco) and 10% (v/v) fetal bovine serum (FBS; Gibco).
MNCs were cultured in the presence of either P0 peptide 180–199
(10 μg/ml; Bio-Synthesis Corporation) or without antigen. The concen-
tration of peptide used was based on previous studies (Xiao et al., 2014;
Zhang et al., 2014). Following incubation for 72 h at 37 °C and 5% CO2,
MTS solution (Promega)was added, and cells were incubated for an ad-
ditional 4 h. The absorbancewasmeasured at 490 nmusing amicrotiter
plate reader (Titertek). Sincewe administered the drug in vivo, we could
not calculate an inhibitory rate. The data are presented as mean OD ±
SEM. The experiment was performed with MNCs from four different
rats in each group, and MNCs from each rat were done in triplicate.
2.7. Fluorescence immunohistochemistry
Following nerve conduction studies, the sciatic nerveswere harvest-
ed as described above and post-ﬁxed in 4% paraformaldehyde overnight
at 4 °C. The nerves were dehydrated sequentially in 15% and then 30%
sucrose until equilibrated. Afterward, nerves were embedded in
Tissue-tek medium (SAKURA) and snap-frozen in liquid nitrogen to ex-
pose antigenic sites for staining. Transverse slices (8 μm)were made on
a cryostat (Leica Microsystems LM3050S) and then mounted on poly-L-
lysine-coated slides and stored at−80 °C.
Fluorescence immunohistochemistry for the frozen specimens was
performed using standard protocols provided by the antibodymanufac-
turers. Brieﬂy, after a 20 min interval to reach room temperature, the
slides were ﬁxed and blocked for half an hour at 37 °C with 3% BSA in
PBS with 0.3% Triton X-100. The mounted tissue was then incubated
overnight at 4 °C with primary antibodies: mouse anti-CD68 (1:200,
Abcam); rabbit anti-CD86 (1:200, Abcam) and goat anti-CD206
(1:200, Santa Cruz Biotechnology) diluted in the same blocking solu-
tion. On the next day, the slides were washed in cold PBS and incubated
for 1 h at room temperature with the following species-appropriate
ﬂuorochrome-conjugated secondary antibodies: Rhodamine (TRITC)
AfﬁniPure donkey anti-goat IgG (H + L) (1:100, Jackson Immuno-
research); Rhodamine (TRITC) AfﬁniPure donkey anti-rabbit IgG
(H+ L) (1:100, Jackson Immunoresearch) and Alexa Fluor® 488 conju-
gated donkey anti-mouse IgG (H+ L) (1:1000, Thermo Fisher Scientif-
ic). After ﬁve more washes, the tissue was coverslipped with ﬂuoro-
shield mounting medium containing DAPI (Abcam) to counterstain
cell nuclei. Immunostaining was visualized with a Coolscope (Nikon).
Positive cell numbers were calculated per square millimeter from
three random microscopic ﬁelds (200× magniﬁcation). All counts
were performed in a blinded fashion.
2.8. Flow cytometry
Spleens were removed under aseptic conditions on dpi 16, and
splenocytes were harvested after lysing red blood cells. 1 × 106 spleen
MNCs resuspended in 100 μl PBS/1% BSAwere co-stained for cell surface
CD11b conjugated with phycoerythrin (1:100, Abcam); MHCIIa markerfor M1 macrophages, was conjugated with APC (1:100, Abcam) and/or
CD206 (1:100, Abcam), a speciﬁc marker for M2 macrophages for
45 min at room temperature following the manufacturer's speciﬁca-
tions. After washing, Alexa Fluor®647-labelled donkey anti-rabbit IgG
(H&L) secondary antibody (1:1000, Abcam was applied for CD206.
MNCs were gated by forward and sideways scatter. Surface molecule
expression was evaluated by detecting the percentage of positive cells.
Cells from all groups were collected and analyzed at each time-point
on the same day with the same cytometer settings. Flow cytometric
data were acquired using a FACSAria™ ﬂow cytometer (BD Biosciences)
and analyzed with FlowJo software version 7.6.1 (ﬂowjo.com).
2.9. Western blot analysis
Total protein was obtained from sciatic nerves stored in liquid nitro-
gen by applying Trizol (Ambion) as the manufacturer instructed. Sam-
ples adjusted to equal content and volume were loaded on 12% SDS-
PAGE gels and electrophoretically separated. Then proteins were trans-
ferred to PVDFmembranes (Millipore). Membranes were blocked in 5%
BSA dissolved in Tris-buffered saline solution for 1 h, followed by over-
night primary antibody incubation at 4 °C. The following antibodies
were used: p-4E-BP1, p-P70S6K, p-Akt, all diluted 1:1000 (Cell Signal-
ing Technology) and actin (1:2000, Zhongshanjinqiao). On the next
day, membranes were washed then, incubated with goat anti-rabbit
IgG or goat anti-mouse IgG conjugated to horseradish peroxidase at a
1:5000 dilution (Transgen Biotech) at room temperature for 1 h. The
protein-speciﬁc signals were detected using a Bio-Rad 721BR08844
Gel Doc Imager (Bio-Rad) and expressed as a fraction of corresponding
β-actin.
2.10. ELISA for cytokine proﬁle
The supernatants of splenicMNCs (2× 106 cells/ml) culturedwith or
without P0 peptide 180–199 (10 μg/ml) were collected after incubation
for 72 h at 37 °C with 5% CO2. Simultaneous quantitative analysis of
twelve cytokines, including IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12, IL-
13, IFN-γ, TNF-α, GM-CSF and RANTES was performed using a multi-
analyte ELISArray Kit (QIAGEN) according to the manufacturer's in-
structions. Determinations were performed in triplicate, and results
are expressed as mean OD ± SEM (n= 4).
2.11. Real-time (RT) quantitative PCR
Total RNA was isolated from splenic cells with Trizol reagent
(Ambion) according to the manufacturer's instructions on dpi 16. The
ﬁrst strand of cDNAwas synthesized from10 μg of RNAwith TransScript
First-Strand cDNA Synthesis SuperMix (Transgen Biotech). RT-PCR was
performed on the Opticon 2 Real-Time PCR Detection System (Bio-Rad)
and SYBR green PCRMasterMix (Roche) using the primers as displayed
in Table 1. Sampleswere run in duplicate at 95 °C for 10min, then 40 cy-
cles at 95 °C for 15 s, and ﬁnally at 60 °C for 1 min. The results were an-
alyzed automatically by an ABI SteponePlus instrument, and the
109R. Han et al. / Experimental Neurology 280 (2016) 106–114method of 2−△△Ct was used to analyze mRNA expression. Expression
levels of the mRNAs were then reported as fold changes vs control.
Results are expressed as mean OD ± SEM (n= 3–5).
2.12. Evaluation and statistical analysis
TheMann-WhitneyU test was used to compare differences between
the control group and treatment groups where appropriate (GraphPad
Prism 5.0). Data are presented as means ± SEM. For all statistical anal-
yses, the level of signiﬁcance was set at p b 0.05.
3. Results
3.1. RAD001 treatment ameliorates symptoms, improves histological
changes and reduces inﬂammatory cell accumulation in EAN rats
RAD001 was applied in two different paradigms tor treating EAN
rats (Fig. 1). For the preventative pattern (blue line), we adminis-
tered RAD001 (1 mg/kg/day) by gavage after immunization to the
peak phase (dpi 16). Alternatively, for the therapeutic patternFig. 1. RAD001 treatment ameliorates the severity of EAN. In a preventative treatment paradig
same dosagewas applied in a therapeutic treatment paradigm fromday 7 to day 16. As a contro
being normal to 10 being so severely impaired that the animals died) were assessed daily po
groups, but the pattern of improvement over time was uneven. The rats in the preventative
from day 10 to day 16 (each group compared separately) with the control group (p b 0.05 on
onset in EAN rats. On dpi 16, sciatic nerves of EAN rats were recovered for H&E staining (D) a
Representative photomicrographs are shown for each group. Arrows in D show the inﬂamma
inﬂammatory cells per mm2 tissue section was evaluated as described in Materials and Meth
were calculated as described in Materials and Methods. Comparisons between the control gro
in D and F is 10 μm. The results are presented as means ± SEM (*p b 0.05 **p b 0.01 for comp
and n= 4 per group for staining). The experiment was repeated 2 times with similar results. R(green line), the same dose of RAD001 was applied only after the
ﬁrst clinical symptoms of the disease appeared. In both RAD001-
treated groups, the scores for severity of EAN decreased; that is, com-
pared to rats in the control group, the preventative treatment group
manifested signiﬁcant better clinical scores from day 7 to day 16
(p b 0.05 on each time point). However, the statistically signiﬁcant
difference occurred 10 to 16 dpi (p b 0.05 on each time point) be-
tween the therapeutic treatment group and the control group. The
mean peak clinical scores were 3.20 ± 0.58, 3.50 ± 0.22, and
6.90 ± 0.29 in the preventative, therapeutic, and control groups, re-
spectively (Fig. 1A and B). Notably, in the preventative treatment
group, the ﬁrst clinical sign of impairment was delayed until day
9.20 ± 0.20 (Fig. 1A and C), whereas such signs appeared sooner in
the therapeutic group at 7.20 ± 0.20 dpi and in the control group
at 6.80 ± 0.20 dpi (Fig. 1C).
We assessed the histopathology of EAN rats' sciatic nerves at the
peak phase of the clinical course (i.e., 16 dpi). H&E staining was used
to exhibit inﬂammatory cell inﬁltration, and LFB staining was applied
to reveal demyelination. Treating EAN rats with RAD001 in both para-
digms (i.e., preventative and therapeutic) not only lowered the countsm, RAD001 was administered from day 1 to day 16 (1 mg/kg, once daily) to EAN rats. The
l condition, EAN rats received an equivalent volume of vehicle. Clinical scores (0–10,with 0
st-immunization (dpi). (A) EAN clinical scores were markedly better in RAD001-treated
and therapeutic group displayed notably better clinical scores from day 7 to day 16 and
each time point). (B\\C) RAD001 improved the peak score and delayed the day of disease
nd LFB staining (F) to assess changes in inﬂammatory cell inﬁltration and demyelination.
tory cells and in F show the demyelination and inﬂammatory cell. The mean number of
ods, and summaries are shown in (E). Mean histological scores are shown in (G). Scores
up and RAD001-treated groups were performed using Mann-Whitney U tests. Scale bar
arison between control and RAD001-treated groups, n= 5 per group for clinical scores
AD001-P, preventative RAD001 group; RAD001-T, therapeutic RAD001 group.
Fig. 3. RAD001 alleviates MNC proliferation Splenic mononuclear cells (MNCs) from each
group were evaluated on dpi 16. After culturing for 72 h in the presence or absence of P0
peptide 180–199 (10 μg/ml), MNC proliferation was analyzed by MTS assay. When
compared to the control group, the RAD001-treatment groups underwent signiﬁcant
reductions in proliferation with (A) or without (B) P0 peptide stimulation. Each
experiment was performed in triplicate for each group. The control group and RAD001-
treated groups were compared by Mann-Whitney U tests. Data shown are means ±
SEM (*p b 0.05 for comparison between control and RAD001-treated groups, n = 4 per
group). The experiment was repeated 2 times with similar results. RAD001-P,
preventative RAD001 treatment; RAD001-T, therapeutic RAD001 treatment.
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demyelination and inﬂammatory cell inﬁltration (Fig. 1F and G).
3.2. RAD001 alleviates EAN-induced peripheral nerve injury
As is well known, EAN-induced peripheral nerve injury can decrease
CMAP amplitude and MNCV as well as lengthening CMAP latency.
Therefore, we estimated the ability of RAD001 to improve this situation
by evoked response electrophysiology at dpi 16 in the sciatic nerve and
gastrocnemiusmuscle. In accordancewith the clinicalﬁndings shown in
Fig. 1, RAD001 alleviated the severity of peripheral nerve deﬁcits in both
RAD001-treated groups (Fig. 2). For the MNCV, the control group's
mean speeds were slower than the preventative and therapeutic
groups' speeds (33.3 ± 1.2 m/s vs. 52.6 ± 3.5 m/s and 46.3 ± 1.2 m/s,
p b 0.05, Fig. 2C). The CMAP mean amplitudes of the two RAD001-
treatment groups were greater (13.4 ± 2.2 mV and 17.3 ± 2.0 mV, re-
spectively, Fig. 2D) compared to those of the control group (7.4 ±
0.6 mV). Also, CMAP latency was shorter in the preventative group
and therapeutic group, showing beneﬁcial effects of RAD001 compared
to the control group's average latency (p b 0.05, Fig. 2E).
3.3. RAD001 ameliorates lymphocyte proliferative responses
MNCs isolated fromEAN rat spleens at the peakphase of disease (dpi
16) were stimulated in vitro with P0 peptide 180–199 (10 μg/ml) or
without peptide for 72 h to assess the effect of RAD001 on lymphocyte
proliferative responses (Fig. 3). Compared to the control group, the
RAD001 recipients in preventative and therapeutic groups showed sig-
niﬁcantly lower levels of lymphocyte proliferation (2.35 ± 0.34 vs.
0.98 ± 0.16, and 0.73± 0.18, respectively) with P0 peptide stimulation
(Fig. 3A, p b 0.05) and the same trend without peptide stimulation
(1.89±0.29 vs. 0.88±0.12, and 0.67±0.14, respectively), as evaluated
by MTS assay.
3.4. RAD001 promotes M2 macrophage polarization in EAN rats
Double-immunohistochemical staining with the macrophage mark-
er CD68 and either CD86, a marker for the M1 phenotype, or CD206, a
marker for the M2 phenotype, was used to identify the proportion ofFig. 2. RAD001 improves peripheral nerve conduction deﬁcits in EAN rats. Representative elec
evoked from stimulation of the ﬁbular head (A) or ankle regions (B) of the sciatic nerve
Compared to the control group, RAD001-treated groups were protected from EAN-induced da
improved amplitudes of CMAPs (D) and also exhibited better distal motor latencies of CMAPs
were compared by Mann-Whitney U testing. Data shown are the means ± SEM (*p b 0.05
experiment was repeated 2 times with similar results. RAD001-P, preventative RAD001 groupM1 andM2 cells in sciatic nerves. The polarization state of MNCs derived
from spleens of rats given RAD001 for treatment or prevention of EAN
was investigated via ﬂow cytometry. In sciatic nerves harvested on dpi
16, RAD001-preventative and RAD001-therapeutic groups both dis-
played elevated local expression of M2 macrophages and reduced
expression of M1 macrophages compared to the control group (Fig. 4A–
C, p b 0.05). Flow cytometric results indicated an elevation of M2 expres-
sion in spleen MNCs. Additionally, both the RAD001-preventative and
RAD001-therapeutic groups showed elevated expression of M2 macro-
phages in EAN spleens compared to the control group (Fig. 4D–E,
p b 0.05).
3.5. RAD001 inhibits p-P70S6K and p-4E-BP1 yet increases p-Akt protein
levels in sciatic nerves of EAN rats
The 4E-BP1 and P70S6K proteins are two main downstream prod-
ucts of the mTOR signaling pathway, and this pathway is regulated by
the level of Akt. Since RAD001 is a potent inhibitor of the mTOR path-
way, we explored the extent of 4E-BP1, P70S6K and Akt activity in sciat-
ic nerves taken from EAN rats on dpi 16. According to Western blottingtrophysiological recordings of motor nerve compound muscle action potentials (CMAPs)
are shown for control, RAD001-P, and RAD001-T rats, respectively, from left to right.
mage of mean motor nerve conduction velocity (MNCV) (C). RAD001-treated groups had
(E) when compared to the control group. The control group and RAD001-treated groups
, for comparison between control and RAD001-treated groups; n = 4 per group). The
; RAD001-T, therapeutic RAD001 group.
Fig. 4. RAD001 promotes M2 macrophage polarization in EAN At the peak phase of EAN after RAD001 treatment, each rat's sciatic nerves were harvested for ﬂuorescent
immunohistochemistry, and spleen mononuclear cells (MNCs) were isolated for ﬂow cytometry, in both cases to analyze the percentage of M1 and M2 macrophages (A) Fluorescence
photomicrographs showed M1 and M2 macrophages in the sciatic nerves of EAN rats. Tissue sections were stained for markers of M1 and M2 macrophages as indicated. Scale bar is
100 μm. (B) Quantitation of immunoﬂuorescence. Counts per mm2 of CD68+/CD86+ cells (M1 phenotype) in sciatic nerves showed that RAD001 reduced the number of M1
macrophages in both RAD001 treatment paradigms. (C) Counts per mm2 of CD68+/CD206+ cells (M2 phenotype) showed that both RAD001-treated groups had increased numbers of
M2 macrophages compared to controls. (D) Flow cytometry of spleen MNCs in EAN rats. (E) Quantitation of ﬂow cytometry. Percentage of M2 macrophages in spleen MNCs was
greater in both RAD001-treated groups compared to the control group. Comparisons to control group were performed using the Mann-Whitney U test; quantitation shows means ±
SEM (*p b 0.05 for comparison between control and RAD001-treated groups; n = 4 per group). The experiment was repeated 2 times with similar results. RAD001-P, preventative
RAD001 treatment; RAD001-T, therapeutic RAD001 treatment.
Fig. 5. RAD001 treatment inhibits theproduction of p-4E-BP1 andp-P70S6K, but increases the level of p-Akt in sciatic nerves of EAN rats Ondpi 16, sciatic nerves of each ratwere harvested
for Western blotting. (A) Western blots of p-4E-BP1, p-P70S6K and p-Akt protein compared to a β-actin standard. RAD001-preventative and RAD001-therapeutic groups had decreased
expression of p-4E-BP1 and p-P70S6K and an increased level of p-Akt in sciatic nerves when compared to the control group. (B–D) Quantitation of Western blots of p-4E-BP1, p-P70S6K
and p-Akt. Relative expression of p-4E-BP1 and p-P70S6K in RAD001-treated groups was signiﬁcantly greater compared to the control group, whereas the level of p-Akt was reversed.
Comparisons to control group were performed using the Mann-Whitney U test; quantitation shows means ± SEM (*p b 0.05 for comparison between control and RAD001-treated
groups; n= 3–4 per group). The experiment was repeated 2 times with similar results. RAD001-P, preventative RAD001 treatment; RAD001-T, therapeutic RAD001 treatment.
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evinced robust localized cellular expression of p-Akt but inhibition of
p-4E-BP1 and p-P70S6K compared to the control group (Fig. 5A–D,
p b 0.05).3.6. RAD001 alters cytokine proﬁle
As is well documented, the expression proﬁles of cytokines affect
the outcome of EAN.We conﬁrmed relevant changes in cytokine pro-
duction in RAD001-treated splenic MNCs by using RT-PCR. That is,
IFN-γ and IL-17 mRNA levels were greatly reduced in RAD001-
treated groups compared to those in the control group, whereas
TGF-β and IL-4 mRNA levels increased signiﬁcantly (Fig. 6A–D,
p b 0.05). Semi-quantitative analysis followed to assess the effects
of RAD001 treatment on the cytokine proﬁles produced in vitro by
MNCs from EAN rats in response to the presence or absence of P0
peptide 180–199 (10 μg/ml). Results from using multi-cytokine
ELISA kits showed that, the production of pro-inﬂammatory cyto-
kines (IL-1α, IFN-γ and RANTES) by MNCs was reduced signiﬁcantly
in both RAD001-treatment groups compared to that in the control
group (Fig. 6E). By contrast, levels of the anti-inﬂammatory cytokine
IL-10 were upregulated. However, no marked differences were re-
corded for the amounts of IL-1β, IL-2, IL-4, IL-6, IL-12, IL-13, TNF-α
or GM-CSF among the three groups. Besides, the differences betweenFig. 6. RAD001 alters cytokine proﬁles Splenic mononuclear cells (MNCs) from each rat were h
rats. Levels of the pro-inﬂammatory cytokines IFN-γ and IL-17 decreased in RAD001-treated gr
(E) Cytokine proﬁles of the supernatants of splenic MNCs cultured with P0 peptide 180–199
greatly, but the level of IL-10 increased compared to the control group. No marked difference
the three groups. Each experiment was performed in triplicate for each group. The control
shown are means ± SEM (*p b 0.05 for comparison between control and RAD001-treated g
RAD001-P, preventative RAD001 treatment; RAD001-T, therapeutic RAD001 treatment.the three groups without antigen stimulation were meaningless
(data not shown).4. Discussion
In this study, we used a classic animal model of GBS, i.e., EAN, to
quantify the effect of RAD001 for treating and/or preventing this dis-
ease. As a result, RAD001 signiﬁcantly ameliorated the symptoms of
EAN rats, documented here by themilder inﬂammatory responses, less-
er demyelination of peripheral nerves and improved nerve conduction
in RAD001-treated groups. Additionally, RAD001 increased the percent-
age of M2 macrophage polarization, as demonstrably related to inhibi-
tion of the mTOR signaling pathway and heightened activation of Akt.
Assessing neurological symptoms through clinical scores, we ob-
served that RAD001 greatly diminished EAN symptoms by reducing
the severity of paralysis, delaying the onset of EAN and decreasing the
peak clinical score. Further, RAD001 generally protected nerves from
EAN-induced peripheral nerve injury by improving MNCV and ampli-
tudes of CMAPs and by reducing the distal motor latency compared to
those values in controls. Histopathologically, EAN is characterized by in-
ﬂammatory cell inﬁltration and nerve demyelination. In the present
study, both preventative and therapeutic RAD001 administration signif-
icantly suppressed the accumulation of inﬂammatory cells and deterred
demyelination when compared to those qualities in the control group.arvested on dpi 16. (A–D) mRNA levels of inﬂammatory cytokines in the MNCs from EAN
oups, but those of the anti-inﬂammatory cytokines TGF-β and IL-4 increased signiﬁcantly.
(10 μg/ml) for 72 h, as measured by ELISA. Levels of IL-1α, IFN-γ and RANTES decreased
s appeared for the levels of IL-1β, IL-2, IL-4, IL-6, IL-12, IL-13 TNF-α and GM-CSF among
group and RAD001-treated groups were compared using Mann-Whitney U tests. Data
roups, n = 3–5 per group). The experiment was repeated 2 times with similar results.
113R. Han et al. / Experimental Neurology 280 (2016) 106–114Overall, these results demonstrated the marked beneﬁcial effects of
RAD001 on EAN rats.
Macrophages are generally divided into two types: classically acti-
vated (M1) and alternatively activated (M2) macrophages (Gordon,
2003).M1-typemacrophages release cytokines that inhibit the prolifer-
ation of surrounding cells and damage contiguous tissue, whereas M2-
type macrophages release cytokines that promote the proliferation of
contiguous cells and repair tissue (Mantovani et al., 2013). Furthermore,
alternatively activated M2 macrophages play an immunomodulatory
role in EAN (Zhang et al., 2012; Zhang et al., 2009), leading to a favorable
outcome. In agreement with those ﬁndings, the present study showed
that the improved outcome of EAN rats was associated with the differ-
entiation of macrophages toward the M2 phenotype. That is, the sciatic
nerves of RAD001-treated EAN rats clearly containedmoreM2-type and
fewer M1-type macrophages. In addition, ﬂow cytometry results con-
ﬁrmed that splenic macrophages in RAD001-treated EAN rats polarized
more toward theM2 type. This combined evidence supported the opin-
ion that RAD001 improved the prognosis of EAN by promotingM2 type
polarization.
The well-known mTORC1-mediated feedback inhibition of Akt sig-
naling (Byles et al., 2013; Carracedo et al., 2008; Song et al., 2012) is re-
inforced by our ﬁndings that inhibiting themTOR signaling pathway via
lowering expression of its target products p-4E-BP1 and p-P70S6K pro-
moted activation of p-Akt (Fig. 7). Although other negative feedback
mechanisms have been described (Shi et al., 2005; Song et al., 2012),
andmay exist in our setting, they act synergistically and ultimately con-
verge to promote Akt activation (O'Reilly et al., 2006). In addition, we
believe that feedback activation of Akt can underlie the enhanced polar-
ization of M2 macrophages (Fig. 7). Vanessa Byles et al. reported that
downregulation of Akt, which may be a response to elevated mTORC1
activation, could impair the activation of M2 macrophages (Byles
et al., 2013). They also asserted that treatment of rapamycin, an mTOR
inhibitor, in vivo modestly increased Akt signaling and M2 responses
(Byles et al., 2013). Guohua Wang et al. proposed that activation ofFig. 7. Proposedmechanism underlying the effect of RAD001 onmacrophage polarization
RAD001 inhibited mTORC1 thereby decreasing the activity of p-P70S6K and p-4E-BP1.
Downregulated p-P70S6K then lost the feedback loop, leading to an increased activation
of phosphatidyl inositol 3-kinase (PI3K). Active PI3K converts phosphatidyl (4,5)-
biphosphate (PIP2) to phosphatidylinositol (3,5)-triphosphate (PIP3), thereby activating
the prosurvival kinase Akt. Activated Akt can then shift macrophages from the
destructive M1 phenotype toward the beneﬁcial M2 phenotype thus eliciting the
protection of peripheral nerves. Rheb, Ras homolog enriched in brain. IRS-1, insulin
receptor substrate 1.Akt in vivo can promote M2 microglia/macrophage polarization,
which in turn may lead to an anti-inﬂammatory effect (Wang et al.,
2015). To the contrary, Mercalli et al. embraced a conﬂicting conclu-
sion after using rapamycin for 3 weeks and ﬁnding an unbalanced di-
version of macrophages to the M1 phenotype (Mercalli et al., 2013).
Su et al attributed the conﬂicting conclusions to a context depen-
dence of mTORC1 function in innate immunity (Su et al., 2015). In
this work we demonstrated that the activation of Akt can partly un-
derlie the polarization of M2 macrophages in EAN rats. The underly-
ing mechanisms for such differences are unknown, probably due to
stimulus- and context-speciﬁc regulatory mechanisms during mac-
rophage polarization. Although our results strongly indicated that
RAD001 modulated macrophage phenotype switching in EAN, previ-
ous study has reported that macrophage polarization induced by
mTOR inhibitor rapamycin was at least partially due to interaction
of macrophages and regulatory T cells (Xie et al., 2014). In addition,
macrophage phenotype switch been accompanied by inhibition of
Th1 and Th17 cells and activation of Th2 and regulatory T cell can
favor the outcome of EAN (Zhang et al., 2009). Therefore, the possi-
bility that cell types other than macrophages mediate RAD001-
induced protective effects (Chi, 2012; Saran et al., 2015; Xie et al.,
2014), especially in EAN, warrants further studies.
RAD001 was veriﬁed as means of ameliorating inﬂammatory re-
sponses in animal models of experimental autoimmune uveoretinitis
(Hennig et al., 2012), autoimmune hepatitis (Ytting and Larsen, 2015)
and in healthy volunteers(Vitiello et al., 2015) as well as in renal trans-
plant recipients (Pereira-Lopes et al., 2013). In accordancewith previous
reports, the present study showed that RAD001 reduced inﬂammatory
responses in EAN rats and favored successful outcomes. RAD001 reduced
themRNA expression of IFN-γ and IL-17, and upregulated themRNA ex-
pression of IL-4 and TGF-β in the spleens of EAN rats. In addition, the
same trend of decreased pro-inﬂammation and increased anti-
inﬂammation cytokine proﬁles were observed in ELISA analyses of su-
pernatants from cultured splenic MNCs. These data revealed that
RAD001's ability to deter destruction by the inﬂammatory environment
was a basis for the protective effect in EAN. Although the spleen samples
used here were taken from animals given RAD001 in vivo, thereforemay
not duplicate changes in peripheral nerves in situ, our data nonetheless
provided mechanistic insight into the physiological activities underpin-
ning this potentially valuable therapeutic strategy. Therefore, the posi-
tive clinical outcome we observed sheds light on a likely solution to a
heretofore inevitable course of disease.5. Conclusions
Wehave demonstrated that RAD001 attenuated EAN through an Akt-
mediated phenotypic shift inmacrophages. The anti-inﬂammatory effects
of RAD001 in EAN, andpossibly its human counterpart, GBS,may improve
the environmental milieu and indirectly exert neuroprotective effects.
RAD001 thus can be a potent candidate for alleviating polyneuritic
disease.Disclosure
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